These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 16460603)

  • 1. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
    McCune JS; Games DM; Espirito JL
    J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
    Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
    Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
    Sverrisdottir A; Nystedt M; Johansson H; Fornander T
    Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy.
    Vehmanen LK; Elomaa I; Blomqvist CP; Saarto T
    Acta Oncol; 2014 Jan; 53(1):75-9. PubMed ID: 23713891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
    Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
    Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
    Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
    J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.
    Vehmanen L; Saarto T; Risteli J; Risteli L; Blomqvist C; Elomaa I
    Breast Cancer Res Treat; 2004 Sep; 87(2):181-8. PubMed ID: 15377842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
    J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer.
    Tiong V; Rozita AM; Taib NA; Yip CH; Ng CH
    World J Surg; 2014 Sep; 38(9):2288-96. PubMed ID: 24700093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    Ganz PA; Hussey MA; Moinpour CM; Unger JM; Hutchins LF; Dakhil SR; Giguere JK; Goodwin JW; Martino S; Albain KS
    J Clin Oncol; 2008 Mar; 26(8):1223-30. PubMed ID: 18227530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
    Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
    Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
    Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.
    Petrek JA; Naughton MJ; Case LD; Paskett ED; Naftalis EZ; Singletary SE; Sukumvanich P
    J Clin Oncol; 2006 Mar; 24(7):1045-51. PubMed ID: 16476708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
    Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
    Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
    JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.